Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor – full-text inclusion checklist for cost-effectiveness

QuestionYesNo
Q1Population

Did the study include a majority of adults with active rheumatoid arthritis who have had an inadequate response to a TNF inhibitor?
Go to Q2Exclude

UD5 = excluded pop
Q2Interventions

Did the interventions include at least one of the following drugs:

Adalimumab?

Etanercept?

Infliximab?

Rituximab?

Abatacept?
Go to Q3Exclude

UD5 = excluded int
Q3Outcomes

Did the study report any quality of life estimates, cost estimates or cost-effectiveness results?
Go to Q4Exclude

UD5 = excluded out
Q4Study design

Was it a cost–consequence analysis, cost–benefit analysis, cost-effectiveness analysis, cost–utility analysis, cost study (UK only), or quality of life study?
Include

UD5 = included
Exclude

UD5 = excluded des

des, design; dur, duration; int, intervention; num, numbers; pop, population; UD5, reference manager User Defined Field 5.

From: Appendix 7, Cost-effectiveness: full paper inclusion/exclusion checklist

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.